Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult

A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk Knudsen says the company is doubling down on innovation and its weight loss pills as it looks toward its next stage of growth.

Fortune

Soriot should explain the curious case of AstraZeneca’s non-deal

AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders

The Guardian - UK

Most big businesses bought zero new petrol or diesel cars for their fleets last year, report reveals

A new report reveals more than 70 per cent of leading fleets have stopped adding combustion-engined vehicles

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol-Myers stock extends gains on reports of a potential merger with AstraZeneca. But caution is warranted in chasing the momentum in BMY shares today.

Barchart

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling

The Guardian - UK

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.

Benzinga

Stocks mixed as AstraZeneca merger talk dents FTSE 100

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca ‘in talks to create £300bn pharmaceutical giant’

IN FULL

The Independent UK

AstraZeneca share prices drop amid £300bn mega-merger talks with US rival

The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company

The Independent UK

AstraZeneca in talks over £300bn mega-merger with US rival – reports

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

Evening Standard

AstraZeneca falls to third-largest UK company amid US merger talks

Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale

The Guardian - UK

UK economy faces recession if strait of Hormuz remains closed, EY warns - as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK

GSK heads to Cambridge with long-awaited positive vibes

Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders

The Guardian - UK

Andhra Pradesh teams up with AstraZeneca for next-gen cancer care model

Andhra Pradesh signed an MoU with AstraZeneca for an integrated precision oncology ecosystem. This initiative will integrate artificial intelligence and advanced genomics for cancer care. The collaboration aims to transform patient journeys from screening to follow-up. AstraZeneca will deploy AI-powered solutions for early lung cancer detection. An Integrated Genomic Solutions…

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

AstraZeneca boss urges western drugmakers to move at ‘Chinese speed’

Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot

Euronews

AstraZeneca quarterly net profit rises 2% on strong cancer drug sales

Strong cancer drug sales lifted Anglo-Swedish pharmaceutical giant AstraZeneca’s second-quarter earnings above expectations, helping the company maintain its 2026 outlook.

Evening Standard

AstraZeneca sales rise as demand for cancer treatments grow

It reported total revenues of 30.67 billion US dollars for the first six months of 2026.

The Independent UK

AstraZeneca sales boosted by soaring demand for cancer treatments

It reported total revenues of 30.67 billion US dollars for the first six months of 2026.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Oil price slides as US and Iran pause fire; cancer treatments help AstraZeneca beat profit forecasts – as it happened

Rolling coverage of the latest economic and financial news

Fortune

Big pharma's patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it

If we slash federal research budgets, we risk hamstringing our scientists and losing an otherwise winnable race.

The Economic Times

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company…

The Independent UK

Mother with breast cancer forced to fundraise £200k for life-extending drug due to ‘unfair’ postcode lottery

Breast Cancer drug Enhertu is not available on the NHS in England and costs about £20,000 for three months privately

Medical Daily

FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor: A Once-Daily Pill That Cuts LDL Cholesterol as Well as Injectables

FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026. The once-daily pill cut LDL by up to 59% in trials. Here's who it's for.

The Economic Times

Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tablets

Natco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent version of AstraZeneca’s Lynparza. The drug addresses a $1.4-billion U.S. market opportunity. The company will manufacture the product, while Alembic Pharmaceuticals will handle its U.S. commercialisation.

The Guardian - UK

Pay gap widens as UK bosses get 130 times average worker’s salary

In its final report the High Pay Centre says the median remuneration of a FTSE 100 CEO has risen to a record £5.06m

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.